TABLE 3.
Comparison of descriptive data between years of investigation using regression model on individual adherent behaviours and other related measures (N = 202)
| Year of investigation | ||||||||
|---|---|---|---|---|---|---|---|---|
| Adherent behaviours | Total | 1(n=57) | 2(n = 66) | 3(N = 79) | ||||
| Mean | Mode | Median | SD | Mean (SD) | Ward X2(2), p-value | |||
| MD3 Adherent behaviours (Range: 0–2) | ||||||||
| 1. Raise the substance use subject respectfully. | 1.36 | 2 | 2 | 0.73 | 0.93a (0.70) | 1.89b (0.43) | 1.22a (0.69) | 46.33, p < .0001 |
| 2. Open-ended questions. | 1.29 | 2 | 1 | 0.78 | 1.32 (0.69) | 1.32 (0.91) | 1.25 (0.72) | 1.30, p = 0.5228 |
| 3. Acknowledge discomfort and/or express genuine concern about patient. | 0.33 | 0 | 0 | 0.60 | 0.44 (0.57) | 0.30 (0.70) | 0.27 (0.52) | 6.29, p = 0.0431 |
| 4. Review current pattern of substance use. | 1.44 | 1 | 1 | 0.50 | 1.05a (0.23) | 1.70b (0.46) | 1.49b (0.50) | 33.20, p < 0.0001 |
| 5. Affirmation/strengths recognition. | 0.53 | 0 | 0 | 0.73 | 0.74 (0.74) | 0.56 (0.84) | 0.35 (0.56) | 8.27 p = 0.0160 |
| 6. Reflections (repeating, rephrasing, paraphrasing or reflection of feeling). | 0.72 | 0 | 1 | 0.77 | 1.07a (0.70) | 0.52b (0.79) | 0.65b (0.72) | 19.12 p < 0.0001 |
| 7. Explore pros/cons of substance use and/or help patient identify discrepancies. | 1.13 | 2 | 1 | 0.82 | 0.79a (0.73) | 1.30b (0.86) | 1.23ab (0.78) | 13.86 p = 0.0010 |
| 8. Assess readiness to change. | 1.06 | 1 | 1 | 0.71 | 0.96 (0.65) | 1.12 (0.81) | 1.08 (0.66) | 1.75 p = 0.4163 |
| 9. Assess confidence. | 0.21 | 0 | 0 | 0.54 | 0.19 (0.44) | 0.24 (0.58) | 0.20 (0.56) | 0.52 p = 0.7695 |
| 10. Provide relevant medical information. | 1.15 | 2 | 1 | 0.79 | 0.82a (0.68) | 1.24b (0.88) | 1.32b (0.71) | 13.43 p = 0.0012 |
| 11. Respectful advice giving. | 1.07 | 1 | 1 | 0.77 | 0.77 (0.60) | 1.18 (0.88) | 1.20 (0.72) | 11.43 p = 0.0033 |
| 12. Goal setting and developing a plan. | 0.29 | 0 | 0 | 0.58 | 0.42a (0.57) | 0.06b (0.35) | 0.39a (0.69) | 14.12 p = 0.0009 |
| 13. Summarise. | 0.42 | 0 | 0 | 0.64 | 0.72a (0.59) | 0.32b (0.68) | 0.29b (0.56) | 22.94 p < .0001 |
| 14. Arrange follow-up and/or referral to treatment (N = 201). | 0.80 | 1 | 1 | 0.72 | 0.79 (0.53) | 0.83 (0.85) | 0.78 (0.73) | 0.1124, p = 0.9454 |
| MD3: Total adherent behaviours (Range, 2–24, N = 202) | 11.80 | 11 | 11 | 4.23 | 11.02 (3.65) | 12.59 (4.54) | 11.71 (4.28) | 4.37, p = 0.1123 |
| MD3: Total non-adherent behaviours (Range, 0–6, N = 202) | 0.46 | 0 | 0 | 0.92 | 0.30 (0.71) | 0.44 (0.75) | 0.59 (1.15) | 2.57, p = 0.2761 |
| MD3: Global ratings (Collaboration) (Range, 1–5, N = 201) | 2.90 | 3 | 3 | 1.01 | 2.82 (0.90) | 2.89 (0.86) | 2.96 (1.19) | 0.63, p = 0.7295 |
| MD3: Global ratings (Empathy) (Range, 1–5, N = 200) | 2.97 | 3 | 3 | 1.00 | 2.79 (0.97) | 3.08 (0.85) | 3.01 (1.12) | 3.12, p = 0.2104 |
| BCCC: Self-assessment (Range, 4–11, N = 235) | 9.25 | 10 | 9 | 1.47 | 9.32 (1.56) | 8.79 (1.51) | 9.61 (1.21) | 2.94 p = 0.2295 |
| BCCC: SP Assessment (Range 2–11, N = 158) | 7.34 | 9 | 7 | 2.42 | -- | 7.12 (2.43) | 7.50 (2.44) | 0.80 p = 0.3713 |
Note:
a,b
Superscripts with different letters indicate significant differences (at p < 0.0025) between cohorts.